Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the First Quarter 2026
Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Application of Dermal Fillers with its Bioneedle Delivery System
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Year Ended 2025
Dermata Announces Appointment of Kyra Peckaitis as Vice President, Marketing
Dermata Opens a New Chapter with the Release of Tome Skincare
Dermata Receives Notice of Grant of Patent for Next-Generation Acne Treatment by Australian Patent Office
Stock Market Today: S&P 500, Dow Jones Futures Trade Mixed Amid Blip In Santa Claus Rally—Boeing, Freeport-McMoRan, Fonar In Focus
Dermata Therapeutics Announces Closing of up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Dermata Therapeutics Announces up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
A New Realm of Skincare is Coming: Dermata Teases New OTC Brand Identity
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
Dermata Announces Acceptance of Patent Application for Next-Generation Acne Treatment by Australian Patent Office
Dermata Therapeutics Announces Presentation of Abstract at the European Academy of Dermatology and Venereology Congress 2025
Dermata Therapeutics Announces Strategic Pivot to Over-the-Counter Skin Care Treatments
Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
Dermata Receives Notice of Grant of Australian Patent for Topical Botulinum Toxin Treatment for Hyperhidrosis
Dermata's XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks
Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
Nano-Cap Dermata Therapeutics Unveils Positive Data From Once Weekly Drug Study For Acne
Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results
Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis
Dermata to Present on BioPub on January 31, 2025
Dermata Expands Patent Portfolio with Issuance of New U.S. Patent for Next-Generation Acne Treatment
Dermata Therapeutics Announces Closing of $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules